Catalent Seeks DEA Nod to Import LSD and Psilocybin
Published Date: 6/30/2026
Notice
Summary
Catalent Pharma Solutions wants to become an official importer of some powerful controlled substances like LSD and psilocybin. People who make or use these drugs can share their thoughts or ask for a hearing by July 30, 2026. This move could impact companies involved in these substances and the government’s control over them.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Import authorization limited — no commercial sales
If registered, Catalent's authorization would be limited to importing the listed substances as finished dosage unit products for clinical trials, research, and analytical activities only. The authorization will not extend to importing FDA‑approved or non‑approved finished dosage forms for commercial sale.
Catalent applied to import Schedule I drugs
Catalent Pharma Solutions applied on May 28, 2026 to be registered to import three Schedule I controlled substances: lysergic acid diethylamide (LSD, code 7315), 5‑Methoxy‑N‑N‑dimethyltryptamine (code 7431), and psilocybin (code 7437). The company says it plans to import finished dosage unit products only for clinical trials, research, and analytical activities.
Public comment and hearing deadline
Registered bulk manufacturers and applicants may submit electronic comments or objections, or file a written request for a hearing, on or before July 30, 2026. Comments must be submitted through https://www.regulations.gov and hearing requests must also be sent to the DEA addresses listed in the notice.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20084, Extension of Reexportation Period.
The DEA is proposing to give companies more time—up to 365 days instead of 180—to send controlled substances back out of the European Economic Area. This change helps businesses avoid rushing and reduces stress around shipping deadlines. If you handle these substances, you can share your thoughts by November 30, 2026.
2026-19840, Christopher Nadorff, M.D.; Decision and Order
Dr. Christopher Nadorff from Ohio lost his DEA registration because he no longer has permission to handle controlled substances in his state. He didn’t ask for a hearing, so the DEA canceled his registration by default. This means he can’t legally prescribe or manage controlled drugs anymore, effective immediately.
2026-19839, Jorge J. Figueroa, M.D.; Decision and Order
Dr. Jorge J. Figueroa from New Jersey lost his DEA registration because he was kicked out of Medicare, Medicaid, and other federal health programs. He didn’t ask for a hearing, so the DEA made the decision official. This means he can’t legally handle controlled substances anymore, effective immediately, impacting his medical practice and income.
Previous / Next Documents
Previous: 2026-13143, Agency Information Collection Activity Under OMB Review: Presidential Memorial Certificate (PMC)
The Department of Veterans Affairs is updating the form used to request Presidential Memorial Certificates, special honors for deceased veterans. If you’re a family member or loved one applying, you’ll notice a small change in how you provide veteran ID info. Comments on this update are open until July 30, 2026, and there’s no cost to apply—just a bit of paperwork to keep the honor rolling smoothly.
Next: 2026-13145, Importer of Controlled Substances Application: Almac Clinical Services Incorp. (ACSI)
Almac Clinical Services Incorp. (ACSI) wants to become an official importer of certain controlled substances, including psilocybin and oxycodone. This affects drug manufacturers and others in the industry who can comment or request a hearing by July 30, 2026. No direct costs are mentioned, but the decision could impact how these substances enter the U.S. market.